Introduction {#S1}
============

Lateral cephalogram (Late. Ceph.) uses a number of landmarks as reference points for analysis/study of craniofacial structures. Sella turcica (ST) serves as one such important landmark in the cranium on Late. Ceph. The sella point or the center of the ST is a point in the cranial base which is situated at the midpoint of ST that accommodates the pituitary gland ([@B8]). It plays an important role in cephalometric analysis and helps us identify pathologies related to pituitary gland and hence becomes an exceptional source of information, specifically those syndromes that affect craniofacial region. A thorough knowledge of its radiological anatomy and variations may help us evaluate the growth and recognize any deviation in a variety of anomalies or pathological situations, and the possible outcome of the orthodontic treatment in such situations.

Congenital anomalies, though identified at birth often, get initiated during pregnancy due to chromosomal abnormalities. A gamut of congenital anomalies occurs in the craniofacial region, cleft lip and palate (CLP) being the most common anomaly in the head and neck region, only second to congenital heart disease in the whole body. Hence, cleft deformities have been included in their Global Burden of Disease initiative, by World Health Organization (WHO). CLP is quite variable in its presentation and affects about 1.17/1000 birth overall 1.30 of every 1000 live births in Saudi ([@B20]) and Asian populations ([@B9]). CLP has a multifactorial etiology with genetics and environmental factors to be the major contributing factors ([@B19]). The clefts have been classified depending upon the extent of involvement and their location as cleft palate, cleft lip, unilateral cleft lip (UCL), unilateral cleft lip and alveolus (UCLA), unilateral cleft lip and palate (UCLP), bilateral cleft lip and palate (BCLP), etc. The affected children may have retarded maxillary growth ([@B1]), malposed teeth, crowding and rotation of teeth, and a high incidence of class III malocclusion ([@B11]).

Most of the previous studies relating to craniofacial anomalies have used 2D imaging, such as Late. Ceph. which was cost-effective with low radiation exposure and the study of various landmarks were done efficiently by linear and angular measurements ([@B3]). The morphology of ST can be efficiently measured with Late. Ceph. With the advancement in radiographic techniques and imaging, there is a shift toward 3D imaging techniques, particularly 3D imaging using CT scan ([@B12],[@B13], [@B14]; [@B15]) and CBCT ([@B22]) as they give a better and accurate extent of the lesions in a 3D view and hence play a key role in the diagnosis and treatment of craniofacial malformations.

Extensive search of literature relating to the measurement of ST revealed that there was only one study on clefts in Saudi population with little or no focus on its relation to ST ([@B3]). Very few studies have evaluated the postnatal development and structure of ST and its relation to clefts ([@B3]; [@B22]) which measured only three parameters to establish the morphology of ST. Due to limited research in this area and alarming number of individuals with clefts without the syndrome in Saudi Arabia with this genotype, the current investigation was undertaken to calculate the seven parameters of morphology of the ST, and to compare the findings with non-cleft (NC) healthy subjects with the following aims:

1.  Investigation of ST bridging, type of skeletal malocclusion, and different dental anomalies.

2.  Gender disparities of seven parameters of morphology of the ST among cleft and NC subjects.

3.  Multiple comparisons of seven parameters of morphology of the ST among four different types of cleft and NC subjects.

Materials and Methods {#S2}
=====================

In this retrospective study, clinical and radiographic details of 31 NC subjects and 92 cleft subjects were used. All the records were collected from Saudi board Dental residents. The research protocol was prepared by one calibrated specialist orthodontist and the data were stored. The protocol was submitted for ethical board review. After approval, data investigations and analysis were completed. The details of ethical approval number are shown in [Table 1](#T1){ref-type="table"}. Out of 92 cleft subjects, 29 had BCLP, 41 had UCLP, nine had UCLA, and 13 had UCL as per cleft classification details from the clinical records. The details of age and gender distribution, demographic details, and inclusion and exclusion criteria are presented in [Table 1](#T1){ref-type="table"}.

###### 

Demographic details and methods.

  Population                            Saudi subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  ------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------- -------------- --------------
  Inclusion and exclusion criteria      Non syndromic cleft subjects with good quality x-ray images. No history of craniofacial surgical treatment besides lip and palate surgery. No orthodontic treatment has been done. No anatomical variation in the ST and sphenoidal regions. Matched with healthy control without any craniofacial deformity. Subjects using hormonal medications or corticosteroids were excluded from the study.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Sampling                              Convenient sampling following inclusion and exclusion criteria.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  **Type of cleft**                                                                                                                                                                                                                                                                                                                                                                                                                          **Non-cleft**       **BCLP**                                                                                                                                                                                                                                                                                                                                                                                                                          **UCLP**       **UCLA**       **UCL**
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Subjects distribution                 Male                                                                                                                                                                                                                                                                                                                                                                                                 14                  19                                                                                                                                                                                                                                                                                                                                                                                                                                26             3              7
                                        Female                                                                                                                                                                                                                                                                                                                                                                                               17                  10                                                                                                                                                                                                                                                                                                                                                                                                                                15             6              6
                                        Total (*N* = 123)                                                                                                                                                                                                                                                                                                                                                                                    31                  29                                                                                                                                                                                                                                                                                                                                                                                                                                41             9              13
  Age                                                                                                                                                                                                                                                                                                                                                                                                                                        13.29 ± 3.52        14.07 ± 4.73                                                                                                                                                                                                                                                                                                                                                                                                                      14.32 ± 4.46   12.78 ± 4.09   13.31 ± 4.46
  Data used                             Digital lateral cephalogram, orthopantomogram, and clinical record details.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Ethical clearance                     Protocol has been presented to the ethical board of Alrass Dental Research Center, Qassim University. Ethical clearance has been obtained with the Code \#: DRC/009FA/20.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  **Method**                            **Artificial intelligence driven technique using Webceph software (Korea)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Landmarks used and the details        TS                                                                                                                                                                                                                                                                                                                                                                                                   Tuberculum sella    The most anterior point of the contour of the sella turcica                                                                                                                                                                                                                                                                                                                                                                                                     
                                        DS                                                                                                                                                                                                                                                                                                                                                                                                   Dorsum sellae       The posterior wall of the sella turcica                                                                                                                                                                                                                                                                                                                                                                                                                         
                                        SF                                                                                                                                                                                                                                                                                                                                                                                                   Sella floor         The deepest point on the floor of pituitary fossa                                                                                                                                                                                                                                                                                                                                                                                                               
                                        Pclin                                                                                                                                                                                                                                                                                                                                                                                                Posterior clenoid   The most anterior point of the PClin process                                                                                                                                                                                                                                                                                                                                                                                                                    
                                        SA                                                                                                                                                                                                                                                                                                                                                                                                   Sella anterior      The most anterior point of the sella                                                                                                                                                                                                                                                                                                                                                                                                                            
                                        SP                                                                                                                                                                                                                                                                                                                                                                                                   Sella posterior     The most posterior point of the sella                                                                                                                                                                                                                                                                                                                                                                                                                           
                                        SM                                                                                                                                                                                                                                                                                                                                                                                                   Sella median        A point midway between PClin and TS                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  **Measurements (seven parameters)**   **Significance/importance**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  a                                     Sella length                                                                                                                                                                                                                                                                                                                                                                                         TS-Pclin            Changes in the size of sella turcica are often identified with the pathology of pituitary gland and may have an undetected hidden disease; hence, sella length is one of the parameters to determine the sella size.                                                                                                                                                                                                                                            
  b                                     Sella width                                                                                                                                                                                                                                                                                                                                                                                          SA-SP               Utilized clinically for pubertal growth phase determination, would be increased by advanced age, it has strong correlation with age.                                                                                                                                                                                                                                                                                                                            
  c                                     Sella diameter                                                                                                                                                                                                                                                                                                                                                                                       TS-DS               Growth of an individual can be assessed based on the diameter of the sella turcica at different age periods.                                                                                                                                                                                                                                                                                                                                                    
  d                                     Sella height anterior                                                                                                                                                                                                                                                                                                                                                                                TS-SF               As the anterior part of the sella turcica is believed to develop mainly from neural crest cell, so we need to measure the sella height anterior. So that, we can assume or determine any structural deviation in the anterior wall which are believed to be associated with the specific deviation in the facial structure.                                                                                                                                     
  e                                     Sella height posterior                                                                                                                                                                                                                                                                                                                                                                               PClin-SF            The posterior part of the sella turcica develops from the para-axial-mesoderm, which develops approximately 7 weeks of gestation. If any disturbance occurs in this area it remains throughout the life, as the time of formation of sella closely associated with the development of maxilla. So that, it may be assumed that any aberration leading to cleft may be associated with some fault at the level of sella turcica.                                 
  f                                     Sella height median                                                                                                                                                                                                                                                                                                                                                                                  SM-SF               Utilized clinically for pubertal growth phase determination, would be increased with age.                                                                                                                                                                                                                                                                                                                                                                       
  g                                     Sella area                                                                                                                                                                                                                                                                                                                                                                                           TS-SA-SF-SP-Pclin   During embryological development of the sella area is the key point for the migration of the neural crest cells to the fronto nasal and maxillary developmental fields. Pituitary fossa increased in size with age and found a positive correlation of the area of the sella to age.                                                                                                                                                                            

Lateral cephalogram X-rays were used to investigate of ST bridging by two observers and the data were recorded after agreement by both the observers and analyzed. In a similar manner, each orthopantomogram (OPG) was investigated and dental anomalies are listed after agreement by both the observers in cases with ST bridging. Late. Ceph. X-ray was also used for skeletal class of malocclusion assessment (based on ANB and Wits measurement) only in cases with ST bridging and seven parameters of ST morphology in all subjects ([@B12],[@B13], [@B14]; [@B15]) were measured by one examiner using artificial intelligence driven Webceph software (Korea). The details of the seven parameters measurements are presented in [Table 1](#T1){ref-type="table"} ([@B12],[@B13], [@B14]; [@B15]) and shown in [Figure 1](#F1){ref-type="fig"} ([@B12],[@B13], [@B14]; [@B15]).

![Lateral cephalogram view of sella turcica in **(A)** BCLP, **(B)** UCLP, **(C)** sella turcica parameters: **(a)** TS-Pclin; **(b)** SA-SP; **(c)** TS-DS; **(d)** TS-SF; **(e)** PClin-SF; **(f)** SM-SF; and **(g)** sella area, **(D)** Control, and **(E)** UCLA subjects.](fcell-08-00656-g001){#F1}

Statistical Analyses {#S2.SS1}
--------------------

After a 2-week interval, 20 randomly selected X-rays were used for re-measurement in a similar fashion. For ST bridging and dental anomalies results were tested using Kappa test for intra and inter-examiner reliability. Error testing in the investigation of ST morphology based on seven parameters measurements were tested by intra-class correlation co-efficient (ICC) test. Total investigated data were analyzed using version 26.0 SPSS software (IBM, Armonk, NY, United States). Normality of the measured seven parameters of ST morphology data was assessed using Kolmogorov--Smirnov test. Descriptive statistics were calculated for each parameter and presented in a tabulated format. Independent *t*-test was used for gender disparities and ANOVA test used for multiple comparison among NC and all four types of cleft groups.

Results {#S3}
=======

Using Kolmogorov--Smirnov test, measured seven parameters of ST morphology data were found normally distributed. Error test results of the ST bridging and dental anomalies investigation showed excellent intra and inter-examiner reliability. ICC results for all seven parameters of ST morphology ranged from 0.86 to 0.94.

Prevalence of ST bridging, type of malocclusion involved, and associated dental anomalies are listed in [Table 2](#T2){ref-type="table"}. Overall, 6.45 and 22.82% ST bridging was found in NC and cleft individuals, respectively. Among four types of clefts, ST bridging found, UCL \> UCLP \> BCLP \> UCLA. Highest % in UCL (30.77%). Skeletal Class III malocclusion was found to be more prevalent in ST bridging individuals. Among dental anomalies, impacted canine, congenital missing, and supernumerary teeth were found to be common.

###### 

Sella turcica bridging, type of malocclusion and associated anomalies.

  Gender   Sella bridging   Subject                                     Skeletal malocclusion   Dental anomalies         Prevalence
  -------- ---------------- ------------------------------------------- ----------------------- ------------------------ -------------------
  F        Complete         Non-cleft                                   Class I                 IC                       Non-cleft = 6.45%
  M        Partial          Non-cleft                                   Class II                IC                       
  F        Partial          Bilateral Cleft Lip and Palate              Class III               CM + IC                  BCLP = 20.69%
  M        Partial          Bilateral Cleft Lip and Palate              Class III               CM                       
  M        Partial          Bilateral Cleft Lip and Palate              Class III               None                     
  M        Partial          Bilateral Cleft Lip and Palate              Class III               CM                       
  M        Partial          Bilateral Cleft Lip and Palate              Class III               CM + IC                  
  M        Partial          Bilateral Cleft Lip and Palate              Class III               None                     
  M        Partial          Unilateral Cleft Lip and Palate Lt Side     Class III               CM                       UCLP = 24.39%
  F        Partial          Unilateral Cleft Lip and Palate Lt Side     Class III               IC                       
  M        Partial          Unilateral Cleft Lip and Palate Lt Side     Class III               CM                       
  F        Complete         Unilateral Cleft Lip and Palate Lt Side     Class III               CM + IC                  
  F        Partial          Unilateral Cleft Lip and Palate Lt Side     Class III               CM + IC                  
  M        Partial          Unilateral Cleft Lip and Palate Lt Side     Class III               IC                       
  F        Complete         Unilateral Cleft Lip and Palate Lt Side     Class III               CM + IC + Dilaceration   
  M        Partial          Unilateral Cleft Lip and Palate Rt Side     Class I                 CM                       
  M        Partial          Unilateral Cleft Lip and Palate Rt Side     Class III               CM + IC                  
  M        Complete         Unilateral Cleft Lip and Palate Rt Side     Class I                 CM                       
  F        Partial          Unilateral Cleft Lip and Alveolus Rt Side   Class III               CM                       UCLA = 11.11%
  F        Complete         Unilateral Cleft Lip Lt Side                Class III               CM                       UCL = 30.77%
  M        Partial          Unilateral Cleft Lip Rt Side                Class III               SN                       
  M        Partial          Unilateral Cleft Lip Rt Side                Class II                CM + IC                  
  F        Complete         Unilateral Cleft Lip Rt Side                Class III               CM                       

Non-cleft = M, male; F, female; IC, impacted canine; CM, congenital missing; SN, supernumerary tooth.

[Table 3](#T3){ref-type="table"} shows the details of descriptive and comparative gender disparities results among NC and different types of clefts (NC, BCLP, UCLP, UCLA, and UCL). Overall ST morphometry has been presented which shows no significant gender disparities.

###### 

Gender disparities of all sella turcica morphomometric parameters among all five groups.

  Group     Variables   Gender   Mean     SD       95% CI    *p*      
  --------- ----------- -------- -------- -------- --------- -------- -------
  Control   A           Male     11.164   1.690    −0.685    1.369    0.501
                        Female   10.822   1.090                       
            B           Male     9.669    1.466    −1.105    1.123    0.987
                        Female   9.659    1.544                       
            C           Male     10.925   3.296    −1.489    2.966    0.503
                        Female   10.187   2.771                       
            D           Male     8.210    1.461    −0.649    1.708    0.366
                        Female   7.681    1.698                       
            E           Male     7.779    0.911    −1.049    1.329    0.812
                        Female   7.639    2.007                       
            F           Male     8.746    1.131    −0.531    1.355    0.379
                        Female   8.335    1.385                       
            G           Male     77.133   22.446   −9.325    23.683   0.381
                        Female   69.954   22.288                      
  BCLP      A           Male     8.075    0.989    −0.390    1.495    0.239
                        Female   7.522    1.480                       
            B           Male     7.422    1.289    −0.520    1.639    0.297
                        Female   6.862    1.455                       
            C           Male     7.663    2.258    −1.330    2.366    0.570
                        Female   7.145    2.398                       
            D           Male     6.254    1.487    −0.897    1.452    0.632
                        Female   5.977    1.420                       
            E           Male     6.229    1.142    −0.876    1.083    0.829
                        Female   6.125    1.368                       
            F           Male     7.210    1.308    −0.928    1.365    0.699
                        Female   6.991    1.650                       
            G           Male     49.767   17.188   −9.614    18.425   0.525
                        Female   45.362   18.076                      
  UCLP      A           Male     8.223    1.266    −0.381    1.308    0.273
                        Female   7.759    1.324                       
            B           Male     7.774    1.492    −1.081    1.018    0.951
                        Female   7.806    1.778                       
            C           Male     9.392    2.418    −1.659    1.480    0.908
                        Female   9.481    2.348                       
            D           Male     6.903    1.227    −1.034    0.513    0.499
                        Female   7.164    1.089                       
            E           Male     6.895    1.054    −0.798    0.549    0.710
                        Female   7.019    0.977                       
            F           Male     7.278    1.158    −0.872    0.582    0.689
                        Female   7.423    1.013                       
            G           Male     57.560   12.685   −6.058    10.327   0.601
                        Female   55.425   12.139                      
  UCL       A           Male     8.873    1.495    −0.940    2.356    0.365
                        Female   8.165    1.141                       
            B           Male     8.034    1.636    −1.968    2.016    0.979
                        Female   8.010    1.616                       
            C           Male     9.739    2.744    −3.412    2.480    0.734
                        Female   10.205   1.923                       
            D           Male     7.199    1.377    −2.404    0.968    0.369
                        Female   7.917    1.378                       
            E           Male     7.543    0.845    −1.474    1.400    0.956
                        Female   7.580    1.474                       
            F           Male     7.711    1.692    −2.626    1.652    0.626
                        Female   8.198    1.810                       
            G           Male     62.428   21.557   −29.800   19.872   0.669
                        Female   67.392   18.638                      
  UCLA      A           Male     8.303    1.414    −2.153    1.033    0.433
                        Female   8.863    0.686                       
            B           Male     8.120    1.026    −3.044    2.150    0.696
                        Female   8.567    1.719                       
            C           Male     10.167   0.257    −3.081    4.514    0.669
                        Female   9.450    2.683                       
            D           Male     6.823    0.770    −2.662    2.129    0.800
                        Female   7.090    1.624                       
            E           Male     6.923    1.822    −3.178    3.048    0.962
                        Female   6.988    1.878                       
            F           Male     7.040    1.574    −3.876    2.599    0.655
                        Female   7.678    2.064                       
            G           Male     54.233   10.970   −39.066   31.380   0.804
                        Female   58.076   23.940                      

\* p \< 0.05 considered statistically significant.

[Table 4](#T4){ref-type="table"} shows the description total details among all five groups (NC, BCLP, UCLP, UCLA, and UCL) subjects. Multiple comparison results are presented in [Table 5](#T5){ref-type="table"}. Significantly larger TS-Pclin has been found in NC group in comparison to all four-cleft group (*p* \< 0.001). However, there are no significant differences within the cleft group found. Smallest value found in BCLP group was 7.884 mm. Sa-SP value shows significant disparities between NC vs BCLP (*p* \< 0.001), NC vs UCLP (*p* \< 0.001), and NC vs UCL (*p* = 0.012) groups. When TS-DS values were compared, NC vs BCLP (*p* \< 0.001), BCLP vs UCLP (*p* = 0.018) and UCL (*p* = 0.037) showed significant disparities. There were significant disparities between NC vs BCLP (*p* \< 0.001) and BCLP vs UCL (*p* = 0.019) in PClin-SF parameter. And, when compared the parameters of SM-SF and TS-SA-SF-SP-PClin, NC vs BCLP and NC vs UCLP shows significant disparities. In BCLP group, values of all seven parameters of ST morphometry showed smallest values in comparison with all four groups.

###### 

Descriptive results of all sella turcica morphomometric parameters among all five groups.

            TS-PClin   SA-SP   TS-DS   TS-SF   PClin-SF   SM-SF   TS-SA-SF-SP-PClin                                                    
  --------- ---------- ------- ------- ------- ---------- ------- ------------------- ------- ------- ------- ------- ------- -------- --------
  Control   10.976     1.379   9.664   1.484   10.520     2.991   7.920               1.592   7.702   1.585   8.521   1.273   73.196   22.281
  BCLP      7.884      1.185   7.229   1.350   7.484      2.278   6.159               1.445   6.193   1.201   7.134   1.409   48.248   17.306
  UCLP      8.053      1.291   7.786   1.580   9.424      2.363   6.999               1.172   6.940   1.016   7.331   1.096   56.779   12.378
  UCL       8.546      1.340   8.023   1.557   9.954      2.316   7.530               1.370   7.560   1.124   7.936   1.691   64.720   19.589
  UCLA      8.677      0.934   8.418   1.470   9.689      2.155   7.001               1.347   6.967   1.742   7.466   1.839   56.795   19.799

###### 

Multiple comparison of all sella turcica morphomometric parameters among all five groups.

  Variables           Multiple comparison   MD   SE     95% CI       *p*-Value                      
  ------------------- --------------------- ---- ------ ------------ ----------- --------- -------- -------
  TS-PClin            Control               vs   BCLP   3.09199\*    0.329       2.150     4.034    0.000
                                                 UCLP   2.92271\*    0.303       2.055     3.790    0.000
                                                 UCL    2.42998\*    0.421       1.226     3.634    0.000
                                                 UCLA   2.29946\*    0.482       0.919     3.680    0.000
                      BCLP                  vs   UCLP   −0.16928     0.309       −1.054    0.715    1.000
                                                 UCL    −0.66202     0.425       −1.879    0.555    1.000
                                                 UCLA   −0.79253     0.486       −2.183    0.598    1.000
                      UCLP                  vs   UCL    −0.49274     0.406       −1.653    0.667    1.000
                                                 UCLA   −0.62325     0.469       −1.965    0.718    1.000
                      UCL                   vs   UCLA   −0.13051     0.552       −1.711    1.450    1.000
  SA-SP               Control               vs   BCLP   2.43493\*    0.386       1.331     3.539    0.000
                                                 UCLP   1.87769\*    0.356       0.860     2.895    0.000
                                                 UCL    1.64047\*    0.494       0.228     3.053    0.012
                                                 UCLA   1.24577      0.566       −0.373    2.864    0.296
                      BCLP                  vs   UCLP   −0.55723     0.363       −1.594    0.480    1.000
                                                 UCL    −0.79446     0.499       −2.221    0.632    1.000
                                                 UCLA   −1.18916     0.570       −2.820    0.442    0.391
                      UCLP                  vs   UCL    −0.23722     0.476       −1.598    1.123    1.000
                                                 UCLA   −0.63192     0.550       −2.205    0.941    1.000
                      UCL                   vs   UCLA   −0.3947      0.648       −2.248    1.459    1.000
  TS-DS               Control               vs   BCLP   3.03586\*    0.646       1.187     4.885    0.000
                                                 UCLP   1.09561      0.595       −0.608    2.799    0.683
                                                 UCL    0.56615      0.827       −1.799    2.931    1.000
                                                 UCLA   0.83111      0.947       −1.879    3.541    1.000
                      BCLP                  vs   UCLP   −1.94025\*   0.607       −3.677    −0.204   0.018
                                                 UCL    −2.46971\*   0.835       −4.858    −0.081   0.037
                                                 UCLA   −2.20475     0.955       −4.936    0.526    0.226
                      UCLP                  vs   UCL    −0.52946     0.796       −2.807    1.749    1.000
                                                 UCLA   −0.2645      0.921       −2.899    2.370    1.000
                      UCL                   vs   UCLA   0.26496      1.085       −2.838    3.368    1.000
  TS-SF               Control               vs   BCLP   1.76106\*    0.358       0.737     2.785    0.000
                                                 UCLP   0.92114      0.330       −0.022    1.864    0.061
                                                 UCL    0.38968      0.458       −0.920    1.699    1.000
                                                 UCLA   0.91857      0.525       −0.582    2.419    0.825
                      BCLP                  vs   UCLP   −0.83992     0.336       −1.801    0.122    0.138
                                                 UCL    −1.37138\*   0.462       −2.694    −0.049   0.037
                                                 UCLA   −0.84249     0.529       −2.355    0.670    1.000
                      UCLP                  vs   UCL    −0.53146     0.441       −1.793    0.730    1.000
                                                 UCLA   −0.00257     0.510       −1.461    1.456    1.000
                      UCL                   vs   UCLA   0.52889      0.601       −1.190    2.247    1.000
  PClin-SF            Control               vs   BCLP   1.50883\*    0.333       0.555     2.463    0.000
                                                 UCLP   0.76169      0.307       −0.117    1.640    0.146
                                                 UCL    0.14194      0.426       −1.078    1.362    1.000
                                                 UCLA   0.73527      0.489       −0.663    2.133    1.000
                      BCLP                  vs   UCLP   −0.74714     0.313       −1.643    0.149    0.186
                                                 UCL    −1.36690\*   0.431       −2.599    −0.135   0.019
                                                 UCLA   −0.77356     0.492       −2.182    0.635    1.000
                      UCLP                  vs   UCL    −0.61976     0.411       −1.795    0.555    1.000
                                                 UCLA   −0.02642     0.475       −1.385    1.333    1.000
                      UCL                   vs   UCLA   0.59333      0.560       −1.008    2.194    1.000
  SM-SF               Control               vs   BCLP   1.38651\*    0.348       0.392     2.381    0.001
                                                 UCLP   1.18991\*    0.320       0.274     2.106    0.003
                                                 UCL    0.58449      0.445       −0.688    1.857    1.000
                                                 UCLA   1.05509      0.510       −0.403    2.513    0.406
                      BCLP                  vs   UCLP   −0.19659     0.327       −1.131    0.738    1.000
                                                 UCL    −0.80202     0.449       −2.087    0.483    0.767
                                                 UCLA   −0.33142     0.513       −1.800    1.138    1.000
                      UCLP                  vs   UCL    −0.60542     0.428       −1.831    0.620    1.000
                                                 UCLA   −0.13482     0.495       −1.552    1.282    1.000
                      UCL                   vs   UCLA   0.4706       0.584       −1.199    2.140    1.000
  TS-SA-SF-SP-PClin   Control               vs   BCLP   24.94809\*   4.584       11.835    38.061   0.000
                                                 UCLP   16.41760\*   4.223       4.336     28.499   0.002
                                                 UCL    8.4768       5.863       −8.295    25.249   1.000
                                                 UCLA   16.40092     6.718       −2.819    35.621   0.161
                      BCLP                       UCLP   −8.53049     4.305       −20.847   3.786    0.499
                                                 UCL    −16.4713     5.922       −33.414   0.471    0.063
                                                 UCLA   −8.54716     6.770       −27.915   10.821   1.000
                      UCLP                       UCL    −7.9408      5.648       −24.097   8.216    1.000
                                                 UCLA   −0.01667     6.531       −18.702   18.668   1.000
                      UCL                        UCLA   7.92413      7.694       −14.087   29.935   1.000

\* p \< 0.05 considered statistically significant.

Discussion {#S4}
==========

Unique quality of this study is that five different groups of subjects were investigated. Only one study has been found based on literature search and used three groups of subjects of Saudi population. ST bridging, type of skeletal malocclusion, and associated dental anomalies at time in a single study have not been investigated before. All seven parameters of ST morphology ([@B12],[@B13], [@B14]; [@B15]) are investigated in this study. Previous studies measured three parameters of ST morphology and ST bridging only ([@B3]; [@B22]).

A thorough knowledge of ST and its variations is very important to identify it from medically compromised patients such as spina bifida or craniofacial deviations ([@B4]). In a study by [@B3], the morphological variations of ST were assessed in CLP patients and it was found that most of the patients had morphological deviations such as irregular posterior wall and double contour of the floor as compared to normally formed ST. Second, in the NC subjects included in the study, the morphology of ST was normal as compared to the people with clefts. In the earlier study, it was shown that ST bridging was 5.5--22% in normal person, while it was 6.45% in the NC individuals. In the present study, it is 22.82% overall in the cleft patients. However, its occurrence was more in patients with craniofacial deviations. ST bridging was 30.77% in subjects with UCL in the present study. Under such circumstances, it draws attention and marks the direction for future research and study if ST bridge exists in normal individuals in the current population.

Various investigations have been done on the morphology of ST with varying techniques ([@B4]; [@B3]; [@B12],[@B13], [@B14]; [@B15]; [@B22]). In the current study, no significant gender disparities of the ST morphology in all seven parameters were found. Taking into account the results of the current and the previous studies ([@B15]; [@B22]), gender disparities were measurably insignificant for all linear and area measurements of ST. According to [@B21], individuals with abnormal ST may suffer from undetected hidden disease. Hence, from an altered state of ST, pathology or anomaly can be identified that may influence the secretion of hormones such as growth hormone, prolactin, follicle stimulating hormone, and thyroid stimulating hormone ([@B2]).

The results revealed significant disparities in different parameters of the ST morphology in cleft subjects (BCLP, UCLP, UCLA, and UCL) as compared to the NC and also among different types of cleft subjects (BCLP, UCLP, UCLA, and UCL). BCLP subjects exhibited smaller measurements in all parameters compared to the other groups. Results revealed disparities in the measured three parameters of ST morphology are smaller ([@B3]) and larger ([@B22]) between cleft subjects than in NC subjects. [@B3] found smaller measurements in UCLP subjects. Yasa at al. found larger values in all three measured parameters in cleft group, only length showed highly significant disparities, however, the type of cleft was not mentioned. In another study, data of 62 subjects with palatally impacted canine revealed significant disparities in ST bridging and three parameters of ST morphology as compared to the control in Saudi population ([@B5]).

Studies in the past have shown that patients with disorders or syndromes such as holoprosencephaly ([@B18]), Down syndrome ([@B14]), spina bifida ([@B16]), CLP ([@B3]; [@B22]), fragile X syndrome ([@B17]), Williams syndrome ([@B4]), and severe craniofacial deformities ([@B6]) have craniofacial malformations which affect the size and/or morphology of ST.

It is well established that the anatomy of ST is variable, and it is of remarkable importance in orthodontics. The anterior form of ST may aid in predicting the patient growth and in surveying craniofacial morphology ([@B7]). An orthodontist should be aware of the normal variations in the ST which might help in identifying any pathology associated with it ([@B10]). The outcomes suggest that ST bridging and altered ST morphology in CLP subjects required careful monitoring of skeletal malocclusion, dental anomalies, and canine eruption are required to diagnosed and guide for better management at an early age.

Conclusion {#S5}
==========

ST bridging, type of skeletal malocclusion, and associated dental anomalies are common in cleft subjects compared to NC subjects. No significant gender disparities were found in four different types of cleft vs NC subjects. All seven parameters of ST morphology are smaller in NC subjects compared to those with clefts. BCLP subjects had smaller measurements in all seven parameters of ST morphology as compared to NC and all other types of cleft subjects.
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